ASP Isotopes (ASPI), through its subsidiary Quantum Leap Energy, has signed a non binding Memorandum of Understanding with a European advanced nuclear reactor developer to explore long term HALEU fuel supply and related enrichment services.

The MOU headlines come as momentum in ASP Isotopes' stock has been building, with a 1 day share price return of 5.86%, 7 day return of 14.08% and 30 day return of 24.90% at a latest share price of US$6.32, while the 1 year total shareholder return is down 3.22% and the 3 year total shareholder return is very large at about 19x.

If this HALEU agreement has you looking across the nuclear fuel chain, it could be worth scanning other listed players through the 87 nuclear energy infrastructure stocks

With ASP Isotopes trading at US$6.32 against an analyst price target of US$13.00 and carrying a low value score of 1, should you view this as potential upside that markets are missing, or assume the recent run already reflects expectations for future growth?

Preferred Price-to-Sales of 31.5x: Is it justified?

ASP Isotopes trades at a P/S of 31.5x, which sits against a last close of $6.32 and points to a rich valuation compared to peers.

P/S compares the company’s market value to its revenue, so a higher ratio usually means investors are paying more for each dollar of current sales, often in anticipation of strong future revenue growth.

For ASP Isotopes, the current P/S of 31.5x implies investors are already pricing in substantial revenue expansion relative to its current $23.85 million in sales and ongoing losses, rather than waiting for profitability to arrive first.

Compared to the US Chemicals industry average P/S of 1.2x and an estimated fair P/S of 5.1x, ASP Isotopes is priced at a multiple that is many times higher than both the sector and the level the market could potentially move toward if expectations cool.

Result: Price-to-Sales of 31.5x (OVERVALUED).

However, the company is still loss making, with a net loss of $175.092 million, and the business is concentrated in early stage nuclear fuel technologies.

Another View: SWS DCF Points to Overvaluation

The SWS DCF model paints a very different picture from the rich 31.5x P/S ratio. On this view, ASP Isotopes at $5.97 is trading above an estimated future cash flow value of $1.83, which suggests the stock screens as overvalued on cash flow assumptions rather than sales multiples.

For you as an investor, that gap means the market price is well ahead of what the SWS DCF model currently supports. The key question is whether future execution and contracts can eventually justify paying so far above that implied value, or if expectations have already run too far.

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out ASP Isotopes for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 47 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

With both risks and rewards in play, does the story so far feel balanced enough for you? Act promptly, review the details, and then weigh up the 2 key rewards and 3 important warning signs.

Looking for more investment ideas?

If this story has sharpened your focus on risk and reward, do not stop here. Use the Simply Wall Street Screener to widen your opportunity set.

• Target dependable cash generators and review 13 dividend fortresses that aim to combine income potential with stability.
• Spot potential mispricings by scanning 47 high quality undervalued stocks where quality fundamentals and discounted valuations come together.
• Reduce portfolio stress by considering 69 resilient stocks with low risk scores that score well on resilience and financial strength.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.